INTRODUCTION

Factor IX (FIX) is a coagulation factor with a pivotal role in the amplification and propagation phases of coagulation process. A deficiency in FIX activity (FIX:C) causes haemophilia B (HB). The FIX gene (F9) (MIM: 300746) has 8 exons and is approximately 32.7kbp long. A number of polymorphisms have been reported in this gene. Of particular interest are the restriction fragment length polymorphisms (RFLPs). These restriction sites include one exonic (MnlI in exon 6), three intronic (XmnI in intron 3, TaqI and MspI in intron 4), two in the 5' flanking region (MseI and BamHI) and one in the 3' untranslated region (UTR) (HhaI). Two other unique complex repeats are found in intron 1 (HinfI/...
DdeI) and in 3’ UTR. These polymorphisms can be employed to determine the inheritance pattern of F9 alleles within families that can thus help in carrier identification.3

Capillary electrophoresis is the current gold standard for mutation analysis and carrier identification in haemophilia.4 With the significant decline in cost in recent years, the facility is increasingly being adopted in developing countries as well.3 However, the classic mode of carrier testing, i.e. linkage analysis is still largely in practice. The test is considerably cheaper but it is cumbersome, time consuming and inconclusive at times.6 The two tests, together with pedigree analysis can be used cost-effectively for prenatal diagnosis and carrier identification in HB families.7

To date, only one study has been conducted on carrier identification in Pakistani HB families.8 The study employed linkage analysis, which was non-conclusive in about 50% of the cases. The five polymorphisms used included DdeI which is previously reported to be the most prevalent among neighboring Indian population.9 The current study reconfirms the heterozygosity rate of DdeI in Pakistani HB population of Khyber Pakhtunkhwa (KP) province and Federally Administered Tribal Areas (FATA). Heterozygosity status for two other polymorphisms, previously non-tested in Pakistani population, is also determined. The study further incorporates pedigree analysis and Sanger sequencing to determine the carrier status in HB families. It also portrays a phenotypic comparison between HB carriers and healthy females from the population, a subject unexplored in Pakistani population.

**METHODS**

**Study duration and settings:** The current study was conducted from March 2014 till February 2016 at Khyber Medical University Peshawar and National Institute of Blood Diseases, Karachi.

**Study participants:** HB families from KP and FATA with F9 mutation previously identified in the index patient were selected. All consenting family members were enrolled into the study after acquisition of informed consent in writing. Those with chronic medical illnesses or with acute infections in the past two weeks were excluded. Female participants using hormonal contraceptives were also not included into the study.

**Preliminary data and bleeding scores:** A family pedigree was constructed for each family and a comprehensive questionnaire depicting demographic and clinical details of the study participants was filled out. Bleeding scores were determined in all the female study participants using International Society on Thrombosis and Haemostasis Bleeding Assessment Tool (ISTH-BAT).10

**Sample collection and haematological investigations:** Blood was collected from all female participants in a 2.7ml Plastic Citrate Tube (catalog # 363083; BD Vacutainer®) and in a 2ml K2EDTA containing plastic tube (catalog # 367841; BD Vacutainer®). Among women of child bearing age, it was collected only in the inter-menstrual period. A complete blood count (CBC) of the collected samples was performed on Sysmex pocH-100i® Automated Hematology Analyzer (Sysmex Corporation, Kobe, Japan). The sample was then stored at 2-8°C until further analysis.

**Haemostasis Investigations:** Platelet poor plasma was extracted from citrated blood. Prothrombin time (PT), activated partial thromboplastin time (APTT) and FIX: C assay were performed on STA COMPACT MAX® (STAGO, US) haemostasis analyzer. Some of the results were cross checked on SYSMEX CA 1500® coagulation analyzer (Kobe, Japan) to establish reliability.

**Linkage analysis:** Three intragenic RFLPs were studied in all the study participants. Description of the selected polymorphisms along with the primers used is given in Table-I.

| Site   | Restriction Enzyme | Forward Primer/Reverse Primer | PCR Alleles    |
|--------|--------------------|--------------------------------|----------------|
| Intron 1 | DdeI               | 5’ GGGACCACCTGTGGTATAATGTGG 3’ | 369 bp and 319 bp |
|         |                    | 5’ CTGGAGGATAGATGTCTCTATCTG 3’ |                |
| Intron 3 | XmnI               | 5’ ATATGAGAATGAGTCTGACTT 3’   | 222 bp and 154+68 bp |
|         |                    | 5’ AAAAGGCCAGATAAGCCCTCA 3’   |                |
| Intron 4 | TaqI               | 5’ CTGGAGTATGACTGCGCGAATATCC 3’ | 163 bp and 124+39 bp |
|         |                    | 5’ GGTACACAAAGGATTCTAAGGT 3’  |                |
DNA sequence analysis: Targeted sequencing was carried out in all the study participants. Corresponding F9 regions were amplified and sequenced on an ABI Prism® 3500 Genetic Analyzer (Applied Biosystems, USA).

DATA analyses: The data was primarily recorded on Microsoft Excel Spread sheets (Microsoft, USA). Statistical analyses were performed using IBM SPSS® (version 22). The threshold for significance was set at a p-value of 0.05. Allele frequencies and heterozygosity rates for the three RFLPs were determined.

RESULTS

We investigated a total of 78 individuals, 30 males and 48 females, from 13 families. The participants included 16 known HB patients, 10 obligate carriers, 36 potential carriers and 16 healthy individuals.

Four families were found to be heterozygous for TaqI polymorphism; five were heterozygous for XmnI polymorphism while three had Ddel polymorphism. In four cases the families were heterozygous for both TaqI and XmnI. Ddel heterozygosity was found in isolation in three families. Taken together, the patterns were conclusive in only three (23%) families and were able to define carrier status in only four (11%) of 36 potential carriers. Ddel polymorphism established definitive carrier status in two families while the other two polymorphisms (TaqI and XmnI) could do so in only one family. Allele frequencies and heterozygosity rates for the three polymorphisms in the 13 families are presented in Table-II.

Sanger sequencing was performed in all study participants and a definitive picture was obtained in all the cases. Among 36 potential carriers, 21 were found to have inherited the disease allele and were hence diagnosed as carriers. Fig.1 depicts chromatograms of randomly selected carriers from the study.

BS was calculated in each female participant. The frequent bleeding complaints included menorrhagia, post-partum haemorrhage, prolonged bleeding after tooth extraction and postsurgical bleeding. The mean bleeding score was significantly higher (p value <0.001) in carriers (0.12±0.332) than the normal females (1.48±1.93). It was further elucidated that the mean bleeding score in carriers of 40 years and above age group (3.67±2.2) was significantly raised (p value 0.001).

![Fig. 1: Chromatograms of four randomly selected carriers from different haemophilia B families.](image)

Note: (A) Mutation c.540-541delAG causing a shift in the sequence frame is expressed in the carrier as an array of dual peaks starting at mutation site. (B) (C) & (D) Heterozygous pattern is marked as dual peaks at mutation sites marked by arrow.
in comparison to that of carriers from age group younger than 40 years (0.96±1.4). None of the study participant, however, had an abnormally raised BS, i.e. > 6 in adult women and >3 in children. Mean FIX:C level in HB carriers was found to be 79.5 ± 22.2. This was significantly lower (p value <0.001) when compared with a mean FIX:C level of 112.6 ±15.4 found in healthy female relatives. Mean FIX: C level in carriers of <40 years age group (FIX:C 78.9 ±24.5) was statistically similar (p value 0.7) to that of ≥40 years age group carriers (FIX:C 81.8 ±7.5).

The mean white blood cell (WBC) count among carriers (10.33±2.61 x 10⁹/l) was significantly raised (p value 0.025) in comparison to that of healthy female group (8.62 ±2.08 x 10⁹/l). It was further found that the mean neutrophil count of carrier group (5.85 ± 1.96 x 10⁹/l) was higher (p value 0.031) than that of healthy females (4.66 ± 1.37 x 10⁹/l). Mixed cells was also found to vary among the two groups (p value 0.014). The mean mixed cells count was 0.85±0.34 x 10⁹/l in carriers and 0.58 ± 0.36 x 10⁹/l in healthy females (Fig.2). No significant difference between the two groups was found in rest of the CBC parameters.

**DISCUSSION**

The study primarily aimed at determining heterozygosity rates for three polymorphisms in HB families from KP and FATA. The secondary objectives included phenotypic assessment of HB carriers. The low frequency of F9 RFLPs shown in the current study discourages their usage as DNA markers for linkage analysis and carrier identification in the Pakistani HB population. A previous study conducted by Imran et al using 5 different F9 RFLPs including Ddel, found a combined heterozygosity of 70% in Pakistani HB families. Increased allele frequencies and higher heterozygosity rate has been reported for the Ddel in the neighboring Indian population. Our findings are, however, consistent with those in Chinese and general Asian populations which report a lower heterozygosity rate.

Direct sequence analysis provides definitive assessment of carrier status in HB. In the present study the procedure was conclusive in all the study participants. F9 is a short gene, so sequence analysis and data interpretation can be performed in a short time at a low cost. It is therefore recommended to employ this technique in determining carrier status, where feasible.

BS provides an insight into the bleeding severity in an individual. In the current study, bleeding scores were found to be significantly raised among the carriers, particularly those above 40 years age. It has been previously established that FIX:C levels increase with age. In our study, however, the two age groups had a comparable mean FIX:C activity. The difference in BS among the two age groups of HB carriers, therefore, pertains to factors other than FIX:C. We hence suggest a study that could explore these factors in the elderly carriers.

The red blood cell (RBC) indices did not significantly vary among the carrier and normal groups. This is not in concordance with the considerably higher BS in the carrier group. Menorrhagia renders a female susceptible to iron deficiency, which in turn may lead to anaemia if not managed well. We could not identify any other study describing haematological parameters in haemophilia carriers. A further exploration of RBC indices, supplemented with iron status in larger groups of haemophilia carriers is suggested.

In the present study a higher WBC count is found in the carriers as compared to healthy females. There are studies which advocate a uniform WBC count throughout the menstrual cycle in healthy females.
females, yet there are others which report significant fluctuation in the counts. In this study the neutrophil and mixed cell counts are significantly higher in the carriers. Although obvious diseases were excluded in the questionnaire, exclusion of subclinical infections was not carried out. The exact counts, in various phases of menstrual cycle, ideally together with sex hormones assessments, in larger carrier groups is recommended for a clearer picture.

CONCLUSION

The study concluded that the three RFLP polymorphisms (Ddel, XmnI and TaqI) have low heterozygosity rates in HB families from KP and FATA and hence have limited diagnostic value. Direct sequence analysis remains a conclusive diagnostic modality. FIX:C activity in carriers is significantly lower than in healthy individuals; the reciprocal is true about BS. The mean WBC count, particularly neutrophil and mixed cell counts, is considerably higher in the HB carriers than the normal females.

ACKNOWLEDGEMENTS

The authors acknowledge the technical help offered by Mr. Shariq Ahmed at NIBD. We also acknowledge the support and assistance of staff of Fatimid Foundation Peshawar, Frontier Foundation Peshawar, and Hamza Foundation Peshawar, Pakistan.

Grant Support & Financial Disclosures: None.

REFERENCES

1. Palta S, Saroa R, Palta A. Overview of the coagulation system. Indian J Anaesth. 2014;58(5):515-523. doi: 10.4103/0019-5049.144643.
2. Rallapalli PM, Kemball-Cook G, Tuddenham EG, Gomez K, Perkins SJ. An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B. J Thromb Haemost. 2013;11(7):1329-1340. doi: 10.1111/j.1538-7836.2013.04276.x.
3. Mitchell M, Keeney S, Goodeve A. The molecular analysis of haemophilia B: a guideline from the UK haemophilia centre doctors’ organization haemophilia genetics laboratory network. Haemophilia. 2005;11(4):398-404. doi: 10.1111/j.1365-2516.2005.01112.x.
4. Goodeve AC. Hemophilia B: molecular pathogenesis and mutation analysis. J Thromb Haemost. 2015;13(7):1184-1195. doi: 10.1111/jth.12958.
5. Behjati S, Tarpey PS. What is next generation sequencing? Arch Dis Child Educ Pract Ed. 2013;98(6):236-238. doi: 10.1136/archdischild-2013-304340.
6. Peyvandi F. Carrier detection and prenatal diagnosis of hemophilia in developing countries. Semin Thromb Hemost. 2005;31(5):344-354. doi: 10.1055/s-2005-922226.
7. Bors A, Andrikovics H, Illés Z, Jager R, Kardos M, Marosi A, et al. Carrier and prenatal diagnostic strategy and newly identified mutations in Hungarian haemophilia A and B families. Blood Coagul Fibrinolysis. 2015;26(2):161-166. doi: 10.1097/MBC.0000000000000212.
8. Imran M, Saeed MT, Mahmood S, Mohsini S, Sohail S, Munir A, et al. A strategy for carrier detection in Pakistani haemophilia B families. Haemophilia. 2012;18(4):e348-e349. doi: 10.1111/j.1365-2516.2012.02860.x.
9. Chowdhury MR, Kabra M, Menon PS. Factor IX gene polymorphisms in Indian population. Am J Hematol. 2001;68(4):246-248. doi: 10.1002/ajh.1189.
10. Rodeghiero F, Tosetto A, Abshire T, Arnold DM, Coller B, James P, et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010;8(9):2063-2065. doi: 10.1111/j.1588-7836.2010.03975.x.
11. Bowen DJ, Thomas P, Webb CE, Bignell P, Peake IR, Bloom AL. Facile and rapid analysis of three DNA polymorphisms within the human factor IX gene using the polymerase chain reaction. Br J Haematol. 1991;77(4):559-560.
12. Peake IR, Lillicrap DP, Boulieu Jenkov V, Briet E, Chan V, Ginter EK, et al. Haemophilia: strategies for carrier detection and prenatal diagnosis. Bull World Health Organ. 1993;71(3-4):429-458.
13. Elbatarny M, Mollah S, Grabell J, Bae S, Deforest M, Tuttle A, et al. Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project. Haemophilia. 2014;20(6):831-835. doi: 10.1111/hae.12503.
14. Boland EJ, Liu YC, Walter CA, Herbert DC, Weaker FJ, Odom MW, et al. Age-specific regulation of clotting factor IX gene expression in normal and transgenic mice. Blood. 1995;86(6):2198-2205.
15. Coad J, Conlon C. Iron deficiency in women: assessment, causes and consequences. Curr Opin Clin Nutr Metab Care. 2011;14(6):625-634. doi: 10.1097/MCO.0b013e32834be6dd.
16. Nowak J, Borkowska B, Pawlowski B. Leukocyte changes across menstruation, ovulation, and mid-luteal phase and association with sex hormone variation. Am J Hum Biol. 2016;28(5):721-728. doi: 10.1002/ajhb.22856.

Authors’ Contribution:

MTMK, AN: Design, data collection, statistical analysis, data interpretation and manuscript writing.
JA: Design, revised the manuscript critically for important intellectual content.
TSS: Review and final approval of manuscript.
AST: Conception, Supervision of the study project, manuscript writing.